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Natural Choice for a Career Path
Being asked to contribute a Master Perspective article
in HEPATOLOGY is a great honor that I accepted with
trepidation. In preparation for this article, I reviewed
the previous ones and realized each tells a different
story. I hope this article will illustrate how much pro-
gress we have made in our understanding of hepatitis B
in the last 30 years. I also hope that my personal jour-
ney will inspire young readers to believe in their dreams
and to strive towards their goals even when the path is
tortuous and riddled with hurdles.
I grew up in Hong Kong in a family where there
had never been a physician. In fact, I was the first in
my family to choose a science track in high school (we
were forced to choose between science and humanity
tracks at the end of 8th grade). My father cautioned
that science is not for girls. When I got a “C” for my
first physics test, I thought I should have listened to the
old man. Fortunately, history did not repeat itself. After
my “O Level” exam (an exam that kids from all schools
take at the end of 11th grade), I applied to a boys’
school with a reputation in science (a move from an
all-girls’ school strong in language and humanities) and
was accepted as the only girl in a class of 31 boys.
Being the odd person out, the boys were super nice and
polite, and the teachers were so sympathetic that I
ended up ranking top of the class 2 years in a row.
When I announced that I would be applying for medi-
cal school at the end of 13th grade (college was an
unnecessary waste of time), my father advised that nurs-
ing would be more appropriate for girls but he was
delighted when I was accepted into medical school.
The 5 years of medical school flew by quickly. After
a year of internship, I was offered a lecturer position in
the Department of Medicine, University of Hong
Kong. There were very few faculty then and residents
like myself were drafted to teach medical students (on
top of all the clinical duties, there were no work-hour
limits). Salaries were the same as other residents with
no teaching duties but the perk was university sponsor-
ship of overseas fellowship training. I fell in love with
hepatology during my first rotation as a resident. Two
people had a big influence on my decision to be a hep-
atologist. Dr. K.C. Lam1 was my attending and Dr.
Rudi Schmid (Chief of Gastroenterology and Hepato-
logy at University of California-San Francisco) was a
visiting professor. Both were inspiring teachers who
asked a lot of questions on rounds and made me think
and want to know more. It is amazing how our lives
are shaped by fate or chance encounter.
As I mentioned earlier, the perk of taking on addi-
tional teaching duties as a resident was sponsorship of
overseas fellowship training. Being a freebie made it
easier for me to get into the best program. The Royal
Free Hospital in London, headed by Dame Sheila
Sherlock, was the mecca of hepatology at that time.
My 2 years at the Royal Free were some of the best
times in my life. The training and experience at the
Royal Free provided solid foundations for my aca-
demic career. Just as important, if not more, I became
a member of the Sherlock Hepatology Family (Fig. 1)
and the Sherlock brand name was a major reason how
I landed with a faculty position in the United States
despite never having any training in the country.
Hepatology was a fairly new specialty in the early
1980s (the Journal HEPATOLOGY was inaugurated in
January 1981). Coming from Hong Kong, it was
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natural for me to choose hepatitis B as the research
focus. Figuring out what topic to study was more diffi-
cult. I knew very little about hepatitis B (still don’t
know enough), had no research experience, and was
not familiar with the research ongoing at that time.
My first meeting with Professor Howard Thomas, my
research mentor, did not go well. I was not able to
articulate what topic I wanted to research on and how
I would go about doing it. It took time, patience, and
perseverance to prove that I was trainable.
Hepatitis B Was Simple Back Then
Hepatitis B in the early 1980s was fairly simple.
Hepatitis B virus (HBV) had been established as a
DNA virus that causes chronic hepatitis and cirrhosis
but an etiological association with hepatocellular carci-
noma (HCC) was still debated. Assays for HBV DNA
were in its infancy. The assays used hybridization with
limit of detection 1 million IU/mL. The results were
usually scored from 0 to 41. The natural history of
chronic HBV infection was thought to comprise two
distinct phases: hepatitis B e antigen (HBeAg)-positive
when virus replication and liver inflammation are
active and HBeAg-negative when virus replication
ceases and liver inflammation subsides. Seroconversion
from HBeAg to HBe antibody (anti-HBe) was thought
to be an irreversible process. There was no approved
treatment for hepatitis B.
Hepatitis B Research: The Early Days
at the Royal Free
Although the tools were crude, the early 1980s was
a golden era for HBV research. Molecular diagnostic
tests were rapidly developing and there were few dis-
tractions. The latter changed by mid 1980s with the
AIDS epidemic and the realization that it was caused
by a virus. Because of the high rate of mortality and
devastating complications affecting mainly young peo-
ple, a lot of funding and resources were earmarked for
human immunodeficiency virus (HIV) research and
many HBV investigators defected. Of those who
stayed, many left in the early 1990s when the elusive
non-A, non-B hepatitis virus was found.
One of my first projects at the Royal Free was to
study the use of interferon (IFN) in the treatment of
chronic hepatitis B. In 1976, Tom Merigan and his
colleagues at Stanford reported promising results in a
study of four patients treated with IFN.2 The IFN we
used was produced by a human lymphoblastoid cell
line (recombinant DNA technology was not available
yet) and administered as an intravenous infusion in
doses of up to 100 million units/m2. Because of the
intensity of the adverse reactions, the infusion had to
be administered by a physician (yours truly) who
would stay by the patient’s bedside for the next few
hours in case a catastrophic reaction occurred. This
early experience spurred the evaluation of lower,
better-tolerated doses. In a study of six patients given
daily (n5 2), alternate day (n5 1), or thrice weekly
(n5 3) intramuscular injections of IFN at 7.5-10 mil-
lion units/m2, we found that thrice weekly administra-
tion of IFN was as effective as daily injections in
inhibiting HBV replication, were associated with fewer
side effects, and could be continued for up to 3
months.3 The rationale for thrice weekly (Monday,
Wednesday, and Friday) versus alternate day adminis-
tration was simply a matter of convenience because
alternate day would require working over the weekend.
Until pegylated IFN became available, thrice weekly
administration of IFN was the norm for hepatitis B. I
have always wondered why no one questioned the
irregular spacing. In hindsight, we would not be able
to tell whether HBV DNA levels crept up during the
weekend gap because the HBV DNA assay used was
not sensitive enough to detect <2-3 log changes. An
“n” of 3 would be considered grossly inadequate
nowadays but the concept of “sample size” had not
been introduced into clinical trial designs in the early
1980s and a schedule designed to make the life of a
young fellow easy was adopted worldwide with no
questions asked.
Following on the heels of the success of IFN, I led
a randomized trial comparing IFN to another antiviral:
adenine arabinoside monophosphate (ARA-AMP),
which had been shown to inhibit HBV replication by
Fig. 1. Dame Sheila Sherlock and the Sherlock Hepatology Family
at the Royal Free Hospital in London on the occasion of Dame Sheila’s
retirement celebration in September 1983. Photo provided by Antonio
Ascione.
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Jay Hoofnagle at the National Institute for Diabetes
and Digestive and Kidney Diseases (NIDDK) and
Tom Merigan at Stanford.4,5 The intention of our trial
was to compare the safety and efficacy of 12 weeks of
IFN versus 4 or 12 weeks of ARA-AMP; however,
during the course of the trial some patients in the 12-
week ARA-AMP group developed peripheral neuropa-
thy and the duration of treatment had to be short-
ened.6 A similar trial at Stanford was terminated early
because of similar adverse events. Seeing young other-
wise healthy patients came back to the clinic limping
in severe pain is a sight that I would never forget. I
am pretty certain we did not mention neuropathy was
a possible adverse event in the consent forms and were
lucky none of the patients pursued legal action. This
experience taught me to be very cautious in reviewing
everything that is known about an experimental drug
before agreeing to be an investigator in any clinical
trial and to have my eyes and ears open for unexpected
events. This trial did show a benefit of IFN and was
one of the studies that laid the foundation for subse-
quent multicenter trials leading to approval of IFN as
treatment for hepatitis B. I presented the results of this
trial during my debut at The Liver Meeting in 1983.
The meeting was held in the Hyatt Hotel in Chicago
with fewer than 1,000 participants.
After a slow start, I was quickly swarmed. My 2-year
fellowship at the Royal Free resulted in a total of 23
papers and book chapters, the meager support (one-third
of my salary in Hong Kong while living in an expensive
city, London) from the University of Hong Kong no
doubt boosted my productivity. It was a lot more fun
and relaxing to stay late at work than to return to a 90-
sq. ft. room that I called home. One of the most inter-
esting papers was in collaboration with Stephanos Had-
ziyannis in Greece. Stephanos was a Sherlock fellow and
had observed that some HBeAg-negative patients contin-
ued to have elevated alanine aminotransferase (ALT) lev-
els in serum and active inflammation in liver biopsies.
He also found a high percent of these patients had
detectable HBV DNA in serum (despite the insensitivity
of the assays at that time). Unfortunately, reviewers and
editors were not convinced. After the paper was rejected
several times, Stephanos turned to Howard Thomas for
advice. Howard in turn asked me (a rookie) to salvage
the paper. We decided to add a control group of British
patients and to retest all samples with the Royal Free
(branded) HBV DNA assay. The paper was accepted by
Gut on first submission.7 Perhaps the editors and
reviewers recognized the significance of the finding—one
of the earliest descriptions of the clinical entity “HBeAg-
negative chronic hepatitis.”
As I was planning my trans-Atlantic trip to my first
American Association for the Study of Liver Diseases
(AASLD) meeting, I thought I should take the oppor-
tunity to visit some of the famous hepatologists and
academic centers that I read so much about. Within 3
weeks I received return mail (this was before faxes and
emails) from NIDDK, Massachusetts General Hospi-
tal, Mayo Clinic, Albert Einstein Medical Center, and
Rockefeller University inviting me to visit and to pres-
ent my research findings. There was no doubt the
Sherlock brand contributed to the warm responses.
Hepatitis B Research: Continuing the
Journey in Hong Kong
In December 1983, I returned to Hong Kong and
was eager to apply everything I learned in London.
The first equipment I requested was a 270C freezer.
Together with C.L. Lai, we established a Hepatitis B
Clinic and assembled a database and serum repository
and I replicated the dot-blot hybridization assay for
HBV DNA. Ready access to a large number of
patients and the lack of an approved treatment for
hepatitis B provided a golden opportunity to study the
natural history of chronic hepatitis B. We described
the different phases of chronic HBV infection, the
rates of spontaneous HBeAg seroconversion and seror-
eversion, and frequency and causes of exacerbations of
chronic hepatitis B. In one of the early articles we
described that young Chinese with chronic hepatitis B
have normal ALT despite high levels of HBV DNA.
One of the reviewers commented that this clinical phe-
notype (immune tolerance) does not exist in Caucasian
patients and the authors should verify these atypical
findings. As Baruch Blumberg mentioned in his book,
“Hepatitis B: The Hunt for a Killer Virus,” when one
challenges the dogma, one has to be prepared that it
would be met with skepticism and be willing to stand
by our own data. Another lesson I learned was that
when you are an unknown entity it takes more effort
to convince others that you and your data can be
trusted. Our description of the “immune tolerance”
phase complemented and confirmed findings of Yun-
Fan Liaw in Taiwan, whose group made some of the
most important contributions to our understanding of
the natural history of chronic hepatitis B.
Following the success of IFN in my London
patients, we conducted two randomized controlled tri-
als of IFN in HBeAg-positive adults and children, but
only 15% of adults and 8% of children lost HBeAg.8,9
These disappointing results led some experts to con-
clude that the poor response in Chinese patients was
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genetically related and Asian patients should not be
considered for IFN therapy. Because IFN was the only
available treatment at that time, I felt a moral obliga-
tion to untie the knot I created. A detailed look at the
patients enrolled in these two trials revealed that most
had normal ALT and were in the immune tolerance
phase. This led us to launch another trial in which
HBeAg-positive patients with normal and those with
abnormal ALT were separately randomized to receive
IFN with or without prednisone priming. The notion
of prednisone priming must seem irrational to our
young readers but this was the fad in the late 1980s
when it was realized that, while corticosteroids
enhance HBV replication, abrupt withdrawal of ste-
roids is often followed by an ALT flare and in some
instances HBeAg seroconversion. The prevailing belief
was that antiviral treatment might be more effective if
it was started when there is a rebound in immune
response triggered by withdrawal of a preceding short
course of steroids. We demonstrated that Chinese
patients with elevated ALT had significantly better
response to IFN than those with normal ALT and their
responses were on par with that of Caucasian patients,
illustrating that the phase of HBV infection/host
immune responsiveness to HBV and not genetic fac-
tors account for the low response rates we reported in
our earlier trials, and prednisone priming had a mar-
ginal benefit on antiviral response.10 High pretreat-
ment ALT remains an important predictor of response
not only to IFN but also nucleos(t)ide analog therapy
to this day. While none of our patients had serious
ALT flares, liver failure and death were observed in
some studies that tested the concept of prednisone
priming.11
The risk of liver failure associated with withdrawal
of immunosuppressive therapy was first reported in the
mid-1970s. After witnessing several patients who died
of HBV-related liver failure despite being cured of
their underlying malignancies, I launched a prospective
study on HBV reactivation in patients receiving chem-
otherapy. This was the first prospective study on HBV
reactivation and it was possible because the oncologists
at the University of Hong Kong recognized the gravity
of the problem and facilitated the study.12 Sadly,
awareness of the risk of HBV reactivation in patients
receiving immunosuppressive therapy remains low 40
years after the initial case reports, although this once
fatal condition can now be easily prevented by screen-
ing of patients for HBV infection prior to start of
immunosuppressive therapy and initiating prophylactic
antiviral therapy in those with moderate-high risk of
HBV reactivation.13
Bold Move or Professional Suicide
In April 1992, I left Hong Kong—my home, my
family, and friends, for the U.S. I was advised to take
it easy after I was promoted to Reader in Medicine
(equivalent to full Professor in the U.S.). Promotion
was based on seniority back then: after being pro-
moted ahead of some more senior colleagues I was
advised to slow down. The notion that I had reached
an academic ceiling when I was still in my 30s moti-
vated the move. I have no family and had never had
any training in the U.S. and took the first position
that offered me a Green Card and a medical license. I
had looked at several positions in the U.S. in the late
1980s but none of those worked out either because I
was not doing basic science research and had never
and likely would never have a publication in Science or
I was not worth the trouble (of securing a Green Card
and a medical license). Some friends were impressed
by my courage while others thought the move was
akin to professional suicide; indeed, many well-
intended hepatologists warned that with the availability
of safe and effective HBV vaccines, hepatitis B would
soon be eradicated and the prevalence of hepatitis B in
the U.S. is so low that that it would not be possible to
secure any funding for hepatitis B research, nor would
there be enough patients to sustain my practice.
Settling in the U.S., a Eureka Moment, and
a Lesson From the Fellowship Days
My first job in the U.S. was in New Orleans at
Tulane University. Two people were pivotal in that
decision: Atilla Ertan, chief of Gastroenterology and a
foreign medical graduate himself who solved the logis-
tical hurdles, and the late Michael Gerber, Chair of
Pathology and a renowned hepatic pathologist pro-
vided opportunities for collaboration. With the discov-
ery of the hepatitis C virus (HCV), the focus of
hepatology research rapidly shifted to hepatitis C. Not
only was there a shift in research priorities and fund-
ing, there was also an exodus of hepatitis B investiga-
tors. It was tempting to defect but my commitment to
hepatitis B research is deeply rooted. Hepatitis B is a
complex disease with many nuances and therefore
intellectual challenges. More important, hepatitis B
affects Asians disproportionately and I have always felt
a moral obligation to find solutions that would
decrease the burden of hepatitis B among Asians.
Earlier on, I mentioned that one of my first articles
was on “HBeAg-negative chronic hepatitis.” In 1989,
Bill Carman, working with Howard Thomas, found
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that patients with HBeAg-negative chronic hepatitis
often harbor a variant of HBV with a stop codon
mutation in the precore region of the HBV sequence,
which prevents HBeAg production.14 This finding
solved the mystery how HBV can continue to replicate
and express hepatitis B core antigen despite not being
able to secrete HBeAg, but it did not explain why
HBeAg-negative chronic hepatitis was more common
in southern Europe and Asia. One evening I stumbled
on an article describing the role of a cis-acting
sequence (e) in the precore region as a signal for
encapsidation of the HBV pregenomic RNA.15 After
staring at one of the figures for half an hour, I experi-
enced a Eureka moment and realized that the precore
region folds back as a stem-loop structure and while
the G1896A (stop codon) mutation stabilizes e when
the opposing nucleotide at position 1858 is a T, as in
the case of HBV genotypes B, D, and some subtypes
of C, it destabilizes e when there is a C at position
1858, as in the case of HBV genotypes A and some
subtypes of C.16 It turns out that the prevalence of
precore HBV variant in different parts of the world is
related to the prevalence of its associating HBV geno-
type and whether the nucleotide opposite 1896 is a C
or T. We published this revelation around the same
time as Shuping Tong (with whom I collaborated in
recent years), who was working with Christian Trepo
in France.17
The 1990s was an exciting period of antiretroviral
drug development for HIV. The resources and exper-
tise in HIV drug development spilled over to HBV
which replicates through reverse transcription of the
pregenomic RNA. In 1994, I was asked to participate
in a multicenter trial of fialuridine, which was shown
to have potent antiviral activity against HBV in pre-
liminary studies. After reviewing the Investigators’ Bro-
chure, I declined participation because some of the
preclinical and pharmacological data reminded me of
ARA-AMP. When news broke that fialuridine caused
mitochondrial toxicity, lactic acidosis, and liver fail-
ure,18 I was relieved that the lesson I learned from
ARA-AMP spared me and my patients from being
exposed to this drug.
Settling in the U.S. was not as difficult as I had
imagined but it took some time to transition from a
national health system where I never had to bill any
patients to a fee-for-service health system in the U.S.
Having published more than 100 papers before I
moved to the U.S. helped launch my research program
but there were times when I had to prove myself
again. Fortunately, there were more believers than
skeptics.
Continuing the Journey in Michigan and
Finally a Hepatitis B Research Network
in North America
After 3.5 years in New Orleans, I accepted a posi-
tion as the Director of Clinical Hepatology at the Uni-
versity of Michigan in October 1995. Michigan had a
strong luminal gastroenterology program but hepato-
logy received very little attention. Having spent most
of my life in tropical climates, many friends predicted
I would not last more than 1-2 winters. The Michigan
Hepatology Program has grown from 5 to 14 full-time
faculty members with expertise in diverse areas of liver
diseases and many faculty and former trainees have
become independently successful investigators with
national and international recognition. It has been a
lot of hard work and there have been many trials and
tribulations but this has been an enjoyable and reward-
ing journey and I feel like a proud mother with every
right to brag about my kids.
By the mid-1990s, it was shown that several antire-
troviral drugs for HIV are safe and have antiviral activ-
ity against HBV. In 1998, the U.S. Food and Drug
Administration (FDA) approved the first oral antiviral
drug for HBV, lamivudine.19,20 This was an exciting
time. Finally, we were able to treat patients with hepa-
titis B with one pill a day. Not only were serum HBV
DNA levels suppressed, ALT levels normalized and
liver histology improved. In patients who presented
with liver failure, jaundice abated and ascites disap-
peared, allowing some patients who were initially listed
for liver transplantation to be taken off the transplant
waiting list. The initial excitement about lamivudine
as a miracle drug was quickly dampened by the realiza-
tion that drug resistance occurs quickly. Nonetheless,
lamivudine saved the lives of many hepatitis B
patients. In most parts of the world, lamivudine has
been replaced by tenofovir and entecavir, which have
higher barriers to resistance.
Fifteen years after approval of the first nucleos(t)ide
analog for hepatitis B, we now have evidence that anti-
viral therapy improves clinical outcomes including
reversal of cirrhosis, prevention of liver failure and
HCC, and the need for liver transplantation.21-23 The
availability of well-tolerated potent oral antiviral drugs
not only decreased the need for liver transplantation
they also revolutionized the prevention of recurrent
hepatitis B after liver transplantation. In the late 1980s
and early 1990s, hepatitis B was considered a contrain-
dication to liver transplantation because HBV reinfec-
tion occurred in 80% of patients and recurrent
hepatitis B was associated with rapidly progressive liver
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failure, resulting in >50% mortality within 2-3 years
of transplant. Although the findings of Didier Samuel
and his colleagues in Europe showed that long-term
intravenous infusion of hepatitis B immune globulin
starting from the anhepatic phase significantly
decreased the incidence of HBV reinfection and mor-
tality from recurrent HBV,24 this approach was very
expensive and ineffective in patients who were viremic
(serum HBV DNA detected by hybridization assay,
roughly >5 log10 IU/mL) at the time of transplant.
This field changed so much in the last 15 years that
my attempt in leading an NIDDK-funded multicenter
study in early 2000 to examine the most cost-effective
strategy to prevent recurrent hepatitis B after liver
transplantation was repeatedly derailed when successive
new antiviral drugs and more sensitive HBV DNA
assays became available during the course of the study.
We ended up abandoning the notion of completing
the planned randomized trials for a pragmatic study
which showed that when appropriate oral antiviral
drugs were administered before and after liver trans-
plantation and rescue therapy was available for viro-
logic breakthrough, HBV recurrence can be kept
below 10% regardless of the dose and duration of hep-
atitis B immune globulin used.25
Implementation of HBV vaccination programs and
universal precautions in healthcare settings have
resulted in a marked decline in the incidence of acute
HBV infection as well as a decrease in the prevalence
of chronic HBV infection in children and adolescents
in the U.S.; however, the prevalence of chronic HBV
infection in adults has remained relatively stable
because of the immigration of chronically infected per-
sons from endemic countries. The U.S. is known to be
a melting pot. In the case of hepatitis B, it is not just
a mix of persons of different races and ethnicities but
also a mix of HBV genotypes (A-H), age at infection
(perinatal, childhood, and adult), and lifestyle and
environmental factors (alcohol, smoking, obesity, etc.).
Thus, data on the natural history of HBV infection
from studies conducted in other countries may not be
applied in the U.S. Similarly, because of changes in
immigration pattern over the years, epidemiological
data of HBV infection in the U.S. in the past may not
apply to the present.
In early 2000, with the recognition that responses
to antiviral treatment of HBeAg-negative chronic hepa-
titis differ from that of HBeAg-positive chronic hepati-
tis, pharmaceutical sponsors began to have separate
protocols for treatment of HBeAg-positive and
HBeAg-negative chronic hepatitis B. In several instan-
ces, U.S. sites were excluded from the trials for
HBeAg-negative chronic hepatitis because it was
thought that HBV genotype A predominated and
HBeAg-negative chronic hepatitis is rarely seen in the
U.S. As a physician who sees patients in the clinic, it
was obvious that these dogmas were incorrect. To rec-
tify these myths, I led a 17-center study in 2002 to
determine the prevalence of HBV genotypes, precore
and basal core promoter variants in the U.S. This
study showed that genotype A was present in 35% of
patients and genotypes B and C (that predominate in
Asian countries) in 53% of patients, supporting data
from other studies that 50-70% of patients with
chronic HBV infection in the U.S. are Asians.26 This
study also showed that precore variants were present in
27% and basal core promoter variants in 44% of
patients, confirming that HBeAg-negative chronic hep-
atitis was not a rare entity in the U.S.
Twenty years after I moved to the U.S. and was told
that hepatitis B will soon be eradicated, it is estimated
as many as 2.2 million persons living in the U.S. have
chronic HBV infection,27 and many questions regard-
ing immunopathogenesis, natural history, and optimal
treatment of hepatitis B remain. It was very gratifying
that in 2008 NIDDK established the Hepatitis B
Research Network (HBRN) which includes 21 adult
and 7 pediatric clinical sites in the U.S. and in
Toronto, Canada. The HBRN has enrolled more than
2,000 adults and children with chronic HBV infection
in the observational cohort studies and launched three
clinical trials of antiviral therapy. The diverse race/eth-
nicity of the patients and entire spectrum of HBV
genotypes from A to H provide a unique opportunity
to examine the impact of host, virus, and environmen-
tal factors on the outcomes of HBV infection that is
not possible with studies in countries where most
patients are of the same race and only one or two
HBV genotypes prevail. It has been an honor and a
privilege to chair the HBRN Steering Committee.
Data from the HBRN are beginning to emerge and
we expect these data will improve our understanding
of the epidemiology and natural history of HBV
Table 1. Milestones in Hepatitis B Development
1965 Discovery of Australia antigen
1970 WHO recommendation to screen blood donors for
Australia antigen
1981 FDA approval of HBV vaccine
1992 FDA approval of interferon as treatment of chronic
hepatitis B
1998 FDA approval of first oral antiviral – lamivudine as
treatment of chronic hepatitis B
2000 U.S. Medicare approval of liver transplantation for hepatitis B
WHO, World Health Organization; FDA, U.S. Food and Drug Administration.
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infection not only in the U.S. but worldwide because
80% of the participants were foreign-born.
Looking Back and Looking Forward
As the first and only (so far) physician in the family,
this has been a remarkable journey. There were many
hurdles along the way but also a lot of triumphs per-
sonally and professionally.
Over the years, I have made many friends, traveled
to many parts of the world, and experienced many cul-
tures. Through participation at hundreds of meetings
and collaboration on multiple projects, I got to know
many iconic figures in hepatology who have inspired
and helped me in my professional development and
made many friends who share not just research ideas
and data but also life experiences and lasting friend-
ship. I have also mentored many fellows and junior
faculty, many of whom have risen through the ranks
and have become internationally recognized leaders:
Bob Fontana, Jorge Marrero, Henry Chan, just to
name a few. My proudest accomplishment is being the
matriarch of the Lok Hepatology Family witnessing
the growth and success of the kids who stay in touch
through an annual family reunion during The Liver
Meeting.
I have been fortunate to be recognized by my peers
and to have received many awards including a Distin-
guished Scientist Award and an autographed book
“Hepatitis B: The Hunt for a Killer Virus” by the late
Nobel laureate Baruch Blumberg from the Hepatitis B
Foundation in 2008, and a Distinguished Service
Award from AASLD in 2011—it meant a lot to be
recognized by the society that I am most closely affili-
ated with and to be placed among other giants in
hepatology whom I admire and respect. After serving
as Councilor at Large of AASLD in 2001-2003, I was
honored to be selected as Councilor again in 2013 and
will serve as President in 2017. I look forward to the
challenges and opportunities of leading the premier
society of our specialty.
As a researcher, being part of the growth of the field
of hepatology and hepatitis B has been an amazing
journey. Table 1 shows the major milestone in HBV
progress and Table 2 shows how far we have come in
the last three decades. As a co-author of the AASLD
guidelines on HBV (with Brian McMahon) for a dec-
ade, I appreciate the opportunity to shape the care of
hepatitis B worldwide.
During the last 30 years, there have been drifts of
investigators and funding from HBV to HIV and then
HCV. With the imminent prospect of HCV cure, it is
gratifying to see a shift back to HBV and a commit-
ment from the scientific community and the pharma-
ceutical industry to find a “cure” for HBV.
In closing, I want to thank the HEPATOLOGY editors for
the honor to contribute this Master’s Perspective. Many
important milestones in HBV progress and many people
who have contributed to the progress and who have
helped me along the way could not be included due to
space constraints. There are a few people I must acknowl-
edge: my mother, who believed girls can be doctors, my
father, who told me I need to work harder (when I was
9), and my brothers, who bear the brunt of taking care
of our elderly parents allowing me to pursue my dreams
guiltlessly. Professionally, I would not be where I am with-
out the inspirations and support from Sir David Todd
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Sherlock in London, and Jay Hoofnagle in the U.S.
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